JP2021502984A - Ｆｘ活性化を促進する第ｘ因子結合剤 - Google Patents

Ｆｘ活性化を促進する第ｘ因子結合剤 Download PDF

Info

Publication number
JP2021502984A
JP2021502984A JP2020526504A JP2020526504A JP2021502984A JP 2021502984 A JP2021502984 A JP 2021502984A JP 2020526504 A JP2020526504 A JP 2020526504A JP 2020526504 A JP2020526504 A JP 2020526504A JP 2021502984 A JP2021502984 A JP 2021502984A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
binding
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020526504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502984A5 (enExample
Inventor
ヤコブ・ルンド
カリーナ・トアン
ミッケル・ノルス・ハーンダール
マリー−アンジュ・ビュイセ
エヴリン・デ・タヴェルニエ
ソレン・ステフェンセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2021502984A publication Critical patent/JP2021502984A/ja
Publication of JP2021502984A5 publication Critical patent/JP2021502984A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020526504A 2017-11-15 2018-11-15 Ｆｘ活性化を促進する第ｘ因子結合剤 Pending JP2021502984A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17201762 2017-11-15
EP17201762.6 2017-11-15
EP18174634.8 2018-05-28
EP18174634 2018-05-28
PCT/EP2018/081296 WO2019096874A1 (en) 2017-11-15 2018-11-15 Factor x binders enhancing fx activation

Publications (2)

Publication Number Publication Date
JP2021502984A true JP2021502984A (ja) 2021-02-04
JP2021502984A5 JP2021502984A5 (enExample) 2021-12-02

Family

ID=64426877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020526504A Pending JP2021502984A (ja) 2017-11-15 2018-11-15 Ｆｘ活性化を促進する第ｘ因子結合剤

Country Status (6)

Country Link
US (2) US11787874B2 (enExample)
EP (1) EP3710486B1 (enExample)
JP (1) JP2021502984A (enExample)
CN (2) CN118745229A (enExample)
MA (1) MA50893A (enExample)
WO (1) WO2019096874A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024020151A (ja) * 2022-07-08 2024-02-14 ノヴォ ノルディスク アー／エス ＦＶＩＩＩ（ａ）の代わりとなることができる非常に効力があるＩＳＶＤ化合物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CN118745229A (zh) * 2017-11-15 2024-10-08 诺和诺德股份有限公司 增强fx活化的因子x结合物
CA3123177A1 (en) 2018-12-21 2020-06-25 Kymab Limited Fixaxfx bispecific antibody with common light chain
AU2020355027A1 (en) 2019-09-23 2022-04-21 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
US12258406B2 (en) * 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
WO2023111018A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Antibodies against coagulation factor x and uses thereof
EP4526333A2 (en) * 2022-05-16 2025-03-26 Celyntra Therapeutics SA Compositions and methods for engineering cells
PE20251082A1 (es) * 2022-07-08 2025-04-10 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011137000A (ja) * 2003-10-10 2011-07-14 Chugai Pharmaceut Co Ltd 機能蛋白質を代替する二種特異性抗体
WO2012067176A1 (ja) * 2010-11-17 2012-05-24 中外製薬株式会社 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
JPH08510555A (ja) 1993-07-01 1996-11-05 デイド、インターナショナル、インコーポレイテッド 第ｘ因子除去血漿の調製のための方法
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
EP3299393A1 (en) * 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1876236B9 (en) 2005-04-08 2015-02-25 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
PT3078743T (pt) 2007-09-28 2020-07-15 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
TW201625299A (zh) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
CN107454906B (zh) 2015-04-17 2022-05-27 豪夫迈·罗氏有限公司 使用凝固因子和多特异性抗体的联合治疗
CN117986372A (zh) 2016-07-29 2024-05-07 中外制药株式会社 显示增加的备选fviii辅因子功能活性的双特异性抗体
BR112019003989A2 (pt) 2016-09-06 2019-05-28 Chugai Pharmaceutical Co Ltd métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado
MX2019005772A (es) 2016-11-23 2019-10-02 Bioverativ Therapeutics Inc Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x.
CN118745229A (zh) * 2017-11-15 2024-10-08 诺和诺德股份有限公司 增强fx活化的因子x结合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011137000A (ja) * 2003-10-10 2011-07-14 Chugai Pharmaceut Co Ltd 機能蛋白質を代替する二種特異性抗体
WO2012067176A1 (ja) * 2010-11-17 2012-05-24 中外製薬株式会社 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KITAZAWA T. ET AL.: "A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia", NAT MED, vol. Vol. 18(10), JPN6022039264, 2012, pages 1570 - 1574, ISSN: 0004877202 *
KITAZAWA T. ET AL.: "Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizum", THROMB HAEMOST, vol. Vol. 117(7), JPN6022039267, 2017, pages 1348 - 1357, ISSN: 0004877204 *
SAMPEI Z. ET AL.: "Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking", PLOS ONE, vol. Vol. 8(2):e57479, JPN6022039266, 2013, ISSN: 0004877203 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024020151A (ja) * 2022-07-08 2024-02-14 ノヴォ ノルディスク アー／エス ＦＶＩＩＩ（ａ）の代わりとなることができる非常に効力があるＩＳＶＤ化合物
JP7459354B2 (ja) 2022-07-08 2024-04-01 ノヴォ ノルディスク アー／エス ＦＶＩＩＩ（ａ）の代わりとなることができる非常に効力があるＩＳＶＤ化合物
JP2024073606A (ja) * 2022-07-08 2024-05-29 ノヴォ ノルディスク アー／エス ＦＶＩＩＩ（ａ）の代わりとなることができる非常に効力があるＩＳＶＤ化合物

Also Published As

Publication number Publication date
MA50893A (fr) 2020-09-23
EP3710486C0 (en) 2025-10-08
EP3710486A1 (en) 2020-09-23
US20210054097A1 (en) 2021-02-25
EP3710486B1 (en) 2025-10-08
US20230416404A1 (en) 2023-12-28
US11787874B2 (en) 2023-10-17
WO2019096874A1 (en) 2019-05-23
CN118745229A (zh) 2024-10-08
CN111386285A (zh) 2020-07-07
CN111386285B (zh) 2024-08-27

Similar Documents

Publication Publication Date Title
US11787874B2 (en) Factor X binders enhancing FX activation
CN110248964B (zh) 促凝血抗体
AU2011208719C1 (en) Anticoagulant antidotes
JP7355874B2 (ja) 改良された血液凝固促進抗体
JP6584397B2 (ja) 凝血促進活性を誘発することができる組織因子経路インヒビターのｎ末端部分を認識する抗体
US11220554B2 (en) Procoagulant antibodies
RU2810748C2 (ru) Усовершенствованные прокоагулянтные антитела
EP4667496A2 (en) Factor x binders enhancing fx activation
RU2810094C2 (ru) Прокоагулянтные антитела
TW201617371A (zh) 針對經活化之因子ｖ之抗體
BR112021000823B1 (pt) ANTICORPOS PRÓ-COAGULANTES CAPAZES DE ESTIMULAR A ATIVIDADE ENZIMÁTICA DE FIXa EM DIREÇÃO A FX, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS DITOS ANTICORPOS E SEU USO NO TRATAMENTO DA HEMOFILIA A

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231108

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240105